Farca SS

Idioma: Español
Referencias bibliográficas: 20
Paginas: 140-142
Archivo PDF: 37.51 Kb.

FRAGMENTO

El desarrollo de un tratamiento médico eficaz para la disolución farmacológica de cálculos de colesterol en la vesícula no ha sido posible aún pero la investigación de la fisiopatología ha ayudado a enfocar mejor la cuestión, en especial el conocimiento de los factores determinantes de la solubilidad del colesterol en la bilis. Como el colesterol biliar puede precipitarse sólo cuando existe en exceso, en relación con las proporciones de otros lípidos biliares (ácidos biliares y lecitina), parecería lógico que si se enriquece la bilis con ácidos biliares se incrementaría la solubilización micelar del colesterol. Pero también se infiere que haya un mecanismo de inhibición de la síntesis de colesterol.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Danzinger, R.G et-al. Effect of oral chenodesoxicholic acid and bile and kinetics and biliary lipid composition in women with cholelithiasis. J Clin Invest 1973; 52: 2809-15.

2. Nathanson, MH. Et al. Mechanisms and regulation of bile secretion. Hepatol, 1991; 14:551-7.

3. Thistle, JR. Et al. Efficacy and specificity of chenodesoxicholic acid therapy for dissolving gallstones. N Engl J Med, 1978;289:665-72.

4. Bazzoli, F. Et al. Acquired gallstones opacification during cholelitholitic treatment with chenodesoxicholic, ursodeoxicolic and taurodesoxicolic acids. Am J Gastroenterol, 1995;90:978-86.

5. Anderson, JM. Chenodesoxicholic acid desaturates bile. But how ? Gastroenterology, 1979;77:1146-55.

6. Inoi, J. Et al. Effect of administration of ursodesoxicholic acid at bedtime on cholesterol saturation of hepatic bile in Japanese patients with gallstones. J Med Invest, 1998;45:115-22.

7. Iser, JH. Et al. Chenodesoxicholic acid treatment of gallstones: a follow-up report and analysis of factors influencing response of therapy. N Engl J Med, 1975; 293:378-88.

8. Maudgal, DP. Et al. A practical guide to the nonsurgical treatment of gallstones. Drugs, 1991;41:185-9.

9. Iser, JH. Et al. Resistance to chenodesoxicholic acid (CDCA) treatment in obese with gallstones. B Med J, 1979:1509-22.

10. Pereira, SP. et al. Gallstone dissolution with oral bile acid therapy. Importance of pretreatment Ct scanning and reasons for nonrespoonse. Dig Dis Sci, 1997:42;1775-80.

11. Tokio Cooperative Gallstones Study Group. Efficiency and indications of Ursodesoxicholic acid treatment for dissolving gallstones. A multicenter doble blind trial. Gastroenterology, 1980;78:542-55.

12. Kano, M. Effects of long term ursodesoxicholate administration on expression levels of secretory low-molecular-weight phopholipases A2 and mucin genes in gallbladders and biliary composition in patients with cholesterol stones. Hepatology, 1998;28:302-06.

13. Jakobs, R. et al. Fluoroscopically guided laser litotripsy versus extracorpòreal shock wave litotripsy for retained bile duct stone: a prospective randomized study. Gut., 1997;40:678-81.

14. Petrom, ML. Et al. Repeated bile acid therapy for the long-term management of cholesterol gallstones. J Hepatol, 1996;25:719-22.

15. Gamba, PG. Et al. Is there a place for medical treatment in children with gallstones ? J pediatr Surg, 1997;32:476-79.

16. Ellis, WR. Et al. Pilot study of combination treatment for gallstones with medium dose chenodesoxicholic acid an a terpene preparation. Br Med J (Clin Res Ed), 1984; 289:953-59.

17. Zhou, J. et al. Lodinated contrast medium as an aid to gallstone dissolution with methyl-tert-butyl ether: in vitro study. Radiology, 1990;1175:479-86.

18. May, GR. et al. Efficacy of bile acid therapy for gallstone dissolution: a meta-analysis of randomized trials. Aliment Pharmacol. Ther, 1993;7:139-45.

19. Tasuma, S. et al. A combination therapy with somvastatine and ursodesoxicholic acid is more effective for cholesterol gallstone dissolution than is ursodesoxicholic acid monotherapy. J Clin Gastro, 1998;26:287-100.

20. Leuschner, U. et al. Gallstone dissolution with methyl-tert-butyl ether in 120 patients: efficacy and safety. Gut, 1991;36:193-201.